Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 23 12:19PM ET
219.64
Dollar change
-5.57
Percentage change
-2.47
%
IndexNDX, S&P 500 P/E27.44 EPS (ttm)8.01 Insider Own0.76% Shs Outstand144.90M Perf Week-4.52%
Market Cap31.98B Forward P/E12.56 EPS next Y17.49 Insider Trans-0.11% Shs Float144.50M Perf Month8.74%
Income1.17B PEG8.57 EPS next Q3.99 Inst Own90.04% Short Float2.18% Perf Quarter-1.65%
Sales9.29B P/S3.44 EPS this Y6.26% Inst Trans0.82% Short Ratio2.57 Perf Half Y-4.32%
Book/sh104.48 P/B2.10 EPS next Y11.81% ROA4.56% Short Interest3.15M Perf Year-28.42%
Cash/sh7.38 P/C29.77 EPS next 5Y3.20% ROE8.04% 52W Range189.44 - 319.76 Perf YTD-15.12%
Dividend Est.- P/FCF- EPS past 5Y-18.05% ROI5.32% 52W High-31.31% Beta-0.02
Dividend TTM- Quick Ratio1.32 Sales past 5Y-4.53% Gross Margin68.31% 52W Low15.94% ATR (14)5.68
Dividend Ex-Date- Current Ratio2.10 EPS Y/Y TTM-62.75% Oper. Margin18.67% RSI (14)49.93 Volatility2.37% 2.68%
Employees7570 Debt/Eq0.46 Sales Y/Y TTM-2.49% Profit Margin12.56% Recom1.60 Target Price285.32
Option/ShortYes / Yes LT Debt/Eq0.44 EPS Q/Q0.93% Payout0.00% Rel Volume0.76 Prev Close225.21
Sales Surprise-0.80% EPS Surprise5.78% Sales Q/Q-5.62% EarningsApr 24 BMO Avg Volume1.23M Price219.64
SMA20-0.74% SMA503.04% SMA200-8.06% Trades Volume428,725 Change-2.47%
Date Action Analyst Rating Change Price Target Change
Feb-14-24Reiterated Needham Buy $305 → $300
Feb-14-24Downgrade Wells Fargo Overweight → Equal Weight $315 → $240
Jan-24-24Downgrade UBS Buy → Neutral $311 → $276
Dec-20-23Resumed Cantor Fitzgerald Overweight $311
Dec-07-23Upgrade Raymond James Mkt Perform → Outperform $283
Sep-06-23Initiated HSBC Securities Buy $360
Jul-27-23Initiated Scotiabank Sector Outperform $327
Jul-24-23Reiterated UBS Buy $346 → $335
May-01-23Upgrade Guggenheim Neutral → Buy $270 → $350
Apr-17-23Upgrade Piper Sandler Neutral → Overweight $280 → $346
Today 10:06AM
08:54AM
May-22-24 07:28PM
09:55AM
08:25AM
07:37AM Loading…
07:37AM
07:30AM
07:19AM
May-21-24 09:50AM
May-17-24 06:15AM
May-16-24 01:37PM
12:46PM
09:29AM
08:50AM
08:05AM
07:51AM Loading…
07:51AM
07:37AM
07:30AM
07:30AM
May-15-24 04:05PM
01:29PM
12:12PM
11:02AM
08:25AM
04:26AM
12:17AM
May-14-24 07:33PM
07:30PM
May-13-24 07:57PM
May-11-24 08:00AM
10:11AM Loading…
May-10-24 10:11AM
May-09-24 06:30AM
May-08-24 03:15PM
02:01PM
07:01AM
May-04-24 10:27AM
May-03-24 12:01PM
May-02-24 07:30AM
Apr-30-24 11:15AM
Apr-29-24 10:03AM
09:50AM
Apr-26-24 11:27AM
05:00AM
01:02AM
Apr-25-24 04:05PM
02:15PM
07:00AM
01:23AM
Apr-24-24 06:18PM
04:19PM
04:01PM
02:12PM
12:57PM
12:45PM
12:28PM
11:53AM
11:13AM
11:08AM
10:39AM
10:28AM
10:05AM
09:39AM
09:34AM
09:30AM
09:00AM
08:39AM
08:32AM
07:45AM
07:15AM
06:48AM
06:45AM
06:45AM
Apr-23-24 12:23AM
Apr-19-24 09:39AM
09:15AM
Apr-17-24 10:01AM
Apr-12-24 10:00AM
Apr-10-24 06:09PM
Apr-01-24 05:50PM
04:02PM
Mar-31-24 07:30PM
11:53AM
Mar-28-24 08:00AM
Mar-27-24 12:18PM
Mar-26-24 11:21AM
Mar-25-24 05:50PM
Mar-22-24 07:05AM
06:57AM
Mar-21-24 05:14PM
09:17AM
04:39AM
Mar-18-24 05:50PM
10:16AM
Mar-15-24 09:34AM
Mar-14-24 11:30AM
Mar-12-24 05:50PM
Mar-11-24 12:44PM
09:00AM
Mar-08-24 04:11PM
04:07PM
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Keeney AdamHead of Corporate DevelopmentMay 01 '24Option Exercise0.009380938May 03 08:00 PM
Singhal PriyaHead of DevelopmentApr 02 '24Sale213.099319,8174,886Apr 03 08:24 PM
Murphy NicoleHead of Pharm Ops and TechApr 01 '24Option Exercise0.0024009,751Apr 03 08:11 PM
Singhal PriyaHead of DevelopmentFeb 22 '24Sale221.2326257,9624,886Feb 26 07:54 PM
Singhal PriyaHead of DevelopmentFeb 16 '24Option Exercise0.001,20805,429Feb 21 09:27 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 16 '24Option Exercise0.005,037052,506Feb 21 09:39 PM
Gregory GingerEVP, Human ResourcesFeb 16 '24Option Exercise0.004,704014,341Feb 21 09:36 PM
Izzar RachidHead of Global Product Strat.Feb 16 '24Option Exercise0.002,017010,014Feb 21 09:33 PM
Kramer RobinChief Accounting OfficerFeb 16 '24Option Exercise0.001,34506,354Feb 21 09:31 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 16 '24Option Exercise0.006,720020,692Feb 21 09:29 PM
Murphy NicoleHead of Pharm Ops and TechFeb 16 '24Option Exercise0.001,26009,624Feb 21 09:28 PM
Singhal PriyaHead of DevelopmentFeb 16 '24Sale221.4910823,9215,148Feb 21 09:27 PM
Rowinsky Eric KDirectorFeb 15 '24Buy222.54455101,25620,629Feb 20 09:13 PM
Singhal PriyaHead of DevelopmentFeb 12 '24Sale239.45419100,3304,516Feb 13 06:06 PM
Singhal PriyaHead of DevelopmentFeb 09 '24Option Exercise0.001,21205,309Feb 13 06:06 PM
Murphy NicoleHead of Pharm Ops and TechFeb 09 '24Option Exercise0.002,27209,529Feb 13 06:04 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 09 '24Option Exercise0.003,257017,555Feb 13 06:03 PM
Kramer RobinChief Accounting OfficerFeb 09 '24Option Exercise0.0083305,523Feb 13 06:01 PM
Gregory GingerEVP, Human ResourcesFeb 09 '24Option Exercise0.002,158011,778Feb 13 06:14 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 09 '24Option Exercise0.002,575050,021Feb 13 05:56 PM
Izzar RachidHead of Global Product Strat.Feb 09 '24Option Exercise0.001,51509,081Feb 13 06:00 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 08 '24Option Exercise0.002,335015,063Feb 09 08:03 PM
Murphy NicoleHead of Pharm Ops and TechFeb 08 '24Option Exercise0.002,10107,895Feb 09 08:01 PM
Kramer RobinChief Accounting OfficerFeb 08 '24Option Exercise0.0078804,943Feb 09 08:06 PM
Gregory GingerEVP, Human ResourcesFeb 08 '24Option Exercise0.001,635010,118Feb 09 08:14 PM
Izzar RachidHead of Global Product Strat.Feb 08 '24Option Exercise0.002,04308,187Feb 09 08:11 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 08 '24Option Exercise0.002,190048,101Feb 09 08:16 PM
Singhal PriyaHead of DevelopmentFeb 02 '24Sale245.93634155,9204,097Feb 05 06:38 PM
Singhal PriyaHead of DevelopmentFeb 01 '24Option Exercise0.001,82805,292Feb 05 06:38 PM
Singhal PriyaHead of DevelopmentDec 11 '23Sale248.0011027,2803,464Dec 12 05:06 PM
Kramer RobinChief Accounting OfficerDec 08 '23Option Exercise0.0035104,325Dec 12 05:02 PM
Singhal PriyaHead of DevelopmentDec 08 '23Option Exercise0.0042603,780Dec 12 05:06 PM
BIOGEN INC.10% OwnerSep 26 '23Sale0.506,000,0003,000,00017,652,466Sep 28 05:30 PM
Singhal PriyaHead of DevelopmentSep 05 '23Sale269.43431116,1243,354Sep 06 06:06 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerSep 01 '23Option Exercise0.005,285014,060Sep 06 06:08 PM
Singhal PriyaHead of DevelopmentSep 01 '23Option Exercise0.001,66804,592Sep 06 06:06 PM
Singhal PriyaHead of DevelopmentJul 03 '23Sale282.878122,9122,924Jul 05 05:33 PM
Singhal PriyaHead of DevelopmentJun 30 '23Option Exercise0.0031503,158Jul 05 05:33 PM
Izzar RachidHead of Global Product Strat.Jun 30 '23Option Exercise0.0050406,388Jul 05 05:37 PM
Kramer RobinChief Accounting OfficerJun 30 '23Option Exercise0.0025204,096Jul 05 05:35 PM
Last Close
May 23 12:19PM ET
11.86
Dollar change
-0.02
Percentage change
-0.17
%
VSTM Verastem Inc daily Stock Chart
Index- P/E- EPS (ttm)-4.40 Insider Own18.79% Shs Outstand25.28M Perf Week-2.23%
Market Cap300.41M Forward P/E- EPS next Y-3.08 Insider Trans-0.41% Shs Float20.57M Perf Month27.39%
Income-105.52M PEG- EPS next Q-0.98 Inst Own49.12% Short Float4.01% Perf Quarter-6.61%
Sales0.00M P/S- EPS this Y0.44% Inst Trans- Short Ratio6.17 Perf Half Y88.85%
Book/sh0.99 P/B11.98 EPS next Y21.78% ROA-86.34% Short Interest0.83M Perf Year115.70%
Cash/sh4.39 P/C2.70 EPS next 5Y1.74% ROE-210.18% 52W Range4.93 - 15.18 Perf YTD45.70%
Dividend Est.- P/FCF- EPS past 5Y24.76% ROI-108.99% 52W High-21.87% Beta0.44
Dividend TTM- Quick Ratio4.40 Sales past 5Y-45.06% Gross Margin- 52W Low140.47% ATR (14)0.70
Dividend Ex-Date- Current Ratio4.40 EPS Y/Y TTM0.92% Oper. Margin0.00% RSI (14)54.12 Volatility7.41% 6.17%
Employees73 Debt/Eq1.14 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price28.79
Option/ShortYes / Yes LT Debt/Eq1.09 EPS Q/Q-34.31% Payout- Rel Volume0.36 Prev Close11.88
Sales Surprise- EPS Surprise-22.16% Sales Q/Q- EarningsMay 09 AMC Avg Volume133.86K Price11.86
SMA205.26% SMA505.97% SMA20021.69% Trades Volume22,515 Change-0.17%
Date Action Analyst Rating Change Price Target Change
Nov-21-23Resumed BTIG Research Buy $27
Sep-27-23Initiated B. Riley Securities Buy $21
Jun-15-23Upgrade Mizuho Neutral → Buy $24 → $36
Sep-07-22Resumed Alliance Global Partners Buy $6
Apr-29-22Resumed Cantor Fitzgerald Overweight $6 → $5
Apr-14-22Initiated RBC Capital Mkts Outperform $5
Mar-09-22Initiated Truist Buy $6
Jul-01-21Initiated Alliance Global Partners Buy $6
May-24-21Upgrade BTIG Research Neutral → Buy $8
Jun-20-19Downgrade BTIG Research Buy → Neutral
May-09-24 10:58PM
04:56PM
04:02PM
May-07-24 07:30AM
Apr-18-24 04:05PM
07:00AM Loading…
Apr-09-24 07:00AM
Apr-04-24 07:30AM
Mar-18-24 07:00AM
Mar-14-24 09:54PM
04:53PM
04:05PM
Mar-11-24 07:30AM
Mar-05-24 05:27PM
04:30PM
Feb-15-24 03:12AM
05:02PM Loading…
Feb-07-24 05:02PM
07:15AM
Jan-29-24 07:00AM
Jan-22-24 08:15AM
Jan-18-24 04:00PM
Jan-11-24 07:00AM
Jan-05-24 07:00AM
Dec-18-23 07:00AM
Dec-13-23 09:08AM
07:00AM
Dec-03-23 04:17PM
Nov-22-23 12:00PM
Nov-13-23 07:00AM
Nov-08-23 05:52PM
04:12PM
07:00AM Loading…
Nov-07-23 07:00AM
Nov-06-23 07:00AM
Oct-26-23 04:05PM
Oct-18-23 04:50PM
Oct-14-23 12:30PM
Oct-06-23 07:00AM
Sep-28-23 02:15PM
Sep-05-23 07:00AM
Sep-04-23 01:23PM
Aug-28-23 07:00AM
Aug-08-23 05:46PM
04:05PM
Jul-11-23 07:00AM
Jul-10-23 04:05PM
Jul-05-23 04:05PM
Jun-16-23 05:00AM
Jun-15-23 04:06PM
04:00PM
May-31-23 09:11AM
May-25-23 05:05PM
May-16-23 07:00AM
May-09-23 04:56PM
04:05PM
May-02-23 07:45AM
May-01-23 07:00AM
Apr-26-23 04:05PM
Apr-18-23 07:05AM
Apr-06-23 05:39PM
04:05PM
Mar-15-23 07:00AM
Mar-14-23 04:05PM
Feb-02-23 07:00AM
Jan-30-23 12:00PM
Jan-24-23 05:46PM
05:45PM
Jan-18-23 04:05PM
Jan-11-23 06:24AM
Dec-15-22 04:30PM
Nov-08-22 08:22AM
Nov-03-22 04:05PM
Oct-20-22 07:00AM
Oct-07-22 04:05PM
Oct-04-22 07:00AM
Sep-19-22 09:31AM
Aug-23-22 12:23PM
Aug-08-22 07:00AM
Jul-27-22 11:40AM
Jul-07-22 07:00AM
Jun-27-22 11:17AM
Jun-07-22 02:26PM
Jun-06-22 07:00AM
May-19-22 06:00PM
May-18-22 08:45AM
May-09-22 04:05PM
08:25AM
Apr-04-22 04:05PM
Mar-28-22 01:46PM
07:05AM
07:00AM
Mar-24-22 07:05AM
Mar-01-22 07:52AM
Feb-22-22 05:00AM
Feb-03-22 05:38PM
Jan-11-22 07:00AM
Jan-07-22 07:00AM
Jan-04-22 04:05PM
Nov-23-21 08:53AM
Nov-22-21 07:30AM
Nov-15-21 06:01AM
Nov-14-21 08:53AM
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Calkins DanielChief Financial OfficerApr 05 '24Sale10.876658,535Apr 08 04:30 PM
Calkins DanielChief Financial OfficerMar 25 '24Sale12.02253008,541Mar 27 04:30 PM
Calkins DanielChief Financial OfficerMar 20 '24Sale11.07556098,566Mar 21 04:31 PM
Stuglik Brian MDirectorMar 19 '24Sale10.382732,83489,640Mar 20 05:32 PM
Paterson DanPresident and CEOMar 19 '24Sale10.381821,88986,490Mar 20 05:34 PM
Gagnon Robert E.DirectorMar 19 '24Sale10.381301,34927,391Mar 20 05:36 PM
Stuglik Brian MDirectorMar 18 '24Sale10.715375,75189,913Mar 20 05:32 PM
Gagnon Robert E.DirectorMar 18 '24Sale10.712833,03127,521Mar 20 05:36 PM
Paterson DanPresident and CEOMar 18 '24Sale10.712442,61386,672Mar 20 05:34 PM
Gagnon Robert E.DirectorFeb 06 '24Sale13.709,204126,09527,804Feb 07 04:00 PM
Gagnon Robert E.DirectorJan 12 '24Sale10.959,204100,78437,008Jan 17 04:00 PM
Calkins DanielChief Financial OfficerJan 05 '24Sale8.506518,621Jan 09 04:03 PM
Calkins DanielChief Financial OfficerDec 26 '23Sale8.08252028,350Dec 28 04:04 PM
Calkins DanielChief Financial OfficerDec 20 '23Sale7.93574528,375Dec 21 04:01 PM
Stuglik Brian MDirectorDec 19 '23Sale7.732742,11890,450Dec 20 04:00 PM
Paterson DanPresident and CEODec 19 '23Sale7.731831,41586,916Dec 20 04:01 PM
Gagnon Robert E.DirectorDec 19 '23Sale7.731301,00546,212Dec 20 04:03 PM
Stuglik Brian MDirectorDec 18 '23Sale7.644873,72190,724Dec 20 04:00 PM
Gagnon Robert E.DirectorDec 18 '23Sale7.642842,17046,342Dec 20 04:03 PM
Paterson DanPresident and CEODec 18 '23Sale7.642441,86487,099Dec 20 04:01 PM
Calkins DanielVice President of FinanceOct 05 '23Sale7.305368,432Oct 10 04:31 PM
Calkins DanielVice President of FinanceSep 25 '23Sale9.40252358,437Sep 25 04:46 PM
Calkins DanielVice President of FinanceSep 21 '23Sale9.312322,1608,462Sep 25 04:46 PM
Stuglik Brian MDirectorSep 19 '23Sale9.842742,69691,211Sep 20 04:15 PM
Paterson DanPresident and CEOSep 19 '23Sale9.841831,80187,343Sep 20 04:15 PM
Gagnon Robert E.DirectorSep 19 '23Sale9.841301,27946,626Sep 20 04:15 PM
Stuglik Brian MDirectorSep 18 '23Sale9.914784,73791,485Sep 20 04:15 PM
Gagnon Robert E.DirectorSep 18 '23Sale9.912782,75546,756Sep 20 04:15 PM
Paterson DanPresident and CEOSep 18 '23Sale9.912402,37887,526Sep 20 04:15 PM
Calkins DanielVice President of FinanceJul 06 '23Sale8.025408,694Jul 10 04:05 PM
Calkins DanielVice President of FinanceJun 26 '23Sale8.17262128,422Jun 28 04:11 PM
Stuglik Brian MChief Executive OfficerJun 20 '23Sale10.302752,83291,963Jun 21 04:23 PM
Paterson DanPresident and COOJun 20 '23Sale10.301831,88537,766Jun 21 04:25 PM
Gagnon Robert E.DirectorJun 20 '23Sale10.301301,33947,034Jun 21 04:24 PM
Stuglik Brian MChief Executive OfficerJun 16 '23Sale9.924874,83192,238Jun 21 04:23 PM
Gagnon Robert E.DirectorJun 16 '23Sale9.922832,80747,164Jun 21 04:24 PM
Paterson DanPresident and COOJun 16 '23Sale9.922442,42037,949Jun 21 04:25 PM
Last Close
May 23 12:16PM ET
1.84
Dollar change
-0.03
Percentage change
-1.60
%
FBIO Fortress Biotech Inc daily Stock Chart
Index- P/E- EPS (ttm)-19.52 Insider Own27.05% Shs Outstand15.09M Perf Week4.55%
Market Cap36.65M Forward P/E- EPS next Y-3.21 Insider Trans0.94% Shs Float14.53M Perf Month2.79%
Income-62.85M PEG- EPS next Q-1.22 Inst Own15.49% Short Float12.07% Perf Quarter5.75%
Sales85.11M P/S0.43 EPS this Y44.39% Inst Trans-12.79% Short Ratio7.05 Perf Half Y-16.36%
Book/sh1.19 P/B1.55 EPS next Y31.92% ROA-25.46% Short Interest1.75M Perf Year-76.84%
Cash/sh4.31 P/C0.43 EPS next 5Y25.50% ROE-179.27% 52W Range1.24 - 10.65 Perf YTD-38.87%
Dividend Est.- P/FCF- EPS past 5Y22.28% ROI-61.58% 52W High-82.72% Beta1.68
Dividend TTM- Quick Ratio1.21 Sales past 5Y26.66% Gross Margin66.76% 52W Low48.39% ATR (14)0.13
Dividend Ex-Date- Current Ratio1.33 EPS Y/Y TTM-37.33% Oper. Margin-137.40% RSI (14)51.83 Volatility8.66% 6.49%
Employees186 Debt/Eq3.85 Sales Y/Y TTM32.48% Profit Margin-73.85% Recom1.00 Target Price13.00
Option/ShortYes / Yes LT Debt/Eq3.43 EPS Q/Q67.40% Payout- Rel Volume0.76 Prev Close1.87
Sales Surprise-7.79% EPS Surprise40.46% Sales Q/Q4.84% EarningsMay 15 AMC Avg Volume248.80K Price1.84
SMA203.66% SMA500.29% SMA200-36.64% Trades Volume86,324 Change-1.60%
Date Action Analyst Rating Change Price Target Change
Mar-15-24Resumed ROTH MKM Buy $10
Aug-04-22Initiated Ladenburg Thalmann Buy $6
Oct-02-20Initiated The Benchmark Company Buy $9
Dec-18-19Initiated B. Riley FBR Buy $9
Feb-28-18Initiated B. Riley FBR, Inc. Buy $10
Jul-11-17Initiated Rodman & Renshaw Buy $11
Mar-22-17Initiated JMP Securities Mkt Outperform
Oct-03-16Initiated ROTH Capital Buy $9
May-16-24 08:30AM
08:00AM
May-15-24 10:53PM
04:32PM
04:15PM
04:01PM Loading…
04:01PM
08:30AM
May-14-24 11:14AM
08:30AM
May-13-24 04:01PM
08:30AM
May-10-24 08:30AM
May-07-24 08:30AM
May-02-24 04:01PM
May-01-24 04:01PM
08:00PM Loading…
Apr-29-24 08:00PM
08:00AM
Apr-25-24 08:30AM
Apr-24-24 07:30AM
Apr-11-24 12:24PM
Mar-28-24 10:53PM
04:05PM
09:00AM
Mar-25-24 08:30AM
Mar-22-24 08:30AM
Mar-21-24 04:01PM
Mar-18-24 04:05PM
08:30AM
08:00AM
Mar-15-24 08:30AM
08:15AM Loading…
08:15AM
Mar-13-24 08:30AM
Mar-12-24 08:30AM
Mar-11-24 04:05PM
08:30AM
08:00AM
Mar-07-24 07:30AM
Mar-04-24 08:30AM
Feb-22-24 08:30AM
Feb-02-24 02:40PM
Jan-29-24 08:00AM
Jan-11-24 08:30AM
08:15AM
08:00AM
Jan-09-24 05:02PM
Jan-05-24 09:15AM
08:30AM
Jan-04-24 08:30AM
Jan-03-24 04:01PM
Jan-02-24 04:05PM
08:30AM
Dec-29-23 08:20AM
Dec-11-23 08:30AM
Dec-06-23 08:30AM
08:30AM
08:00AM
Dec-05-23 08:30AM
Dec-01-23 08:30AM
Nov-16-23 11:18PM
Nov-14-23 04:29PM
04:10PM
04:05PM
04:01PM
Nov-13-23 05:00PM
04:05PM
Nov-10-23 08:15AM
Nov-09-23 05:05PM
Nov-07-23 04:01PM
Nov-02-23 03:00PM
09:28AM
Oct-31-23 09:15AM
08:30AM
Oct-30-23 02:15PM
Oct-26-23 12:30PM
09:00AM
Oct-20-23 08:30AM
Oct-18-23 08:30AM
Oct-16-23 09:00AM
Oct-09-23 12:50PM
Oct-05-23 08:30AM
Oct-02-23 12:53PM
Sep-21-23 08:30AM
Sep-07-23 08:30AM
08:15AM
Sep-06-23 08:30AM
08:00AM
Sep-05-23 08:30AM
Aug-16-23 08:00AM
Aug-14-23 04:19PM
04:15PM
04:05PM
04:01PM
Aug-10-23 04:15PM
Aug-08-23 04:01PM
Aug-03-23 08:30AM
08:00AM
Aug-02-23 04:01PM
Aug-01-23 02:54PM
08:30AM
Jul-31-23 08:30AM
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Klein DovDirectorMay 20 '24Sale1.8910,00018,90053,400May 20 04:56 PM
ROSENWALD LINDSAY A MDPresident, CEO & ChairmanMay 16 '24Buy1.7610,00017,5892,873,905May 20 05:00 PM
ROSENWALD LINDSAY A MDPresident, CEO & ChairmanJan 05 '24Buy2.3850,000118,7702,863,905Jan 09 08:15 AM
ROSENWALD LINDSAY A MDPresident, CEO & ChairmanNov 14 '23Buy1.701,567,5152,664,7762,597,440Nov 16 05:50 PM
WEISS MICHAEL SSee RemarksNov 14 '23Buy1.70147,058249,9991,130,520Nov 16 05:46 PM
ROSENWALD LINDSAY A MDPresident, CEO & ChairmanSep 26 '23Buy0.28100,00028,33015,449,091Sep 27 08:20 AM
Fortress Biotech, Inc.10% OwnerSep 08 '23Buy0.72418,410301,2551,032,390Sep 12 09:02 AM
ROSENWALD LINDSAY A MDPresident, CEO & ChairmanAug 18 '23Buy9.3410,00093,400112,500Aug 21 08:30 AM
ROSENWALD LINDSAY A MDPresident, CEO & ChairmanAug 17 '23Buy11.7510,000117,500102,500Aug 21 08:30 AM